Therapeutic targeting of IL-17A-driven PTGS2/NLRP3 inflammasome activation in juvenile myelomonocytic leukemia.

In PTPN11-mutant juvenile myelomonocytic leukemia, dual NLRP3 and PTGS2 inhibition combined with MEK blockade significantly prolongs survival and reduces leukemic burden in models.

• Why it matters: JMML, especially with PTPN11 mutations, has poor outcomes with current treatments, highlighting the need for targeted therapies that address immune suppression and inflammation driving disease progression.
• What they did: Using a mouse model and patient samples, the study identified an IL-17A/PTGS2/NLRP3 signaling axis that promotes inflammation and leukemic growth, and tested combined inhibition of these pathways along with MEK blockade.
• The result: The combined therapy suppressed inflammasome activity, restored T-cell function, reduced leukemia cell growth, and improved survival, supporting its potential as a promising treatment for high-risk JMML.